Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes

https://doi.org/10.2337/dc18-0787

OBJECTIVE

Pediatric type 2 diabetes prevalence is increasing, with β-cell dysfunction key in its pathogenesis. The RISE Pediatric Medication Study compared two approaches—glargine followed by metformin with metformin alone—in preserving or improving β-cell function in youth with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes during and after therapy withdrawal.

RESEARCH DESIGN AND METHODS

Ninety-one pubertal, overweight/obese 10–19-year-old youth with IGT (60%) or type 2 diabetes of <6 months duration (40%) were randomized to either 3 months of insulin glargine with a target glucose of 4.4–5.0 mmol/L followed by 9 months of metformin or to 12 months of metformin alone. β-Cell function (insulin sensitivity paired with β-cell responses) was assessed by hyperglycemic clamp at baseline, 12 months (on treatment), and 15 months (3 months off treatment).

RESULTS

No significant differences were observed between treatment groups at baseline, 12 months, or 15 months in β-cell function, BMI percentile, HbA1c, fasting glucose, or oral glucose tolerance test 2-h glucose results. In both treatment groups, clamp-measured β-cell function was significantly lower at 12 and 15 months versus baseline. HbA1c fell transiently at 6 months within both groups. BMI was higher in the glargine followed by metformin versus metformin alone group between 3 and 9 months. Only 5% of participants discontinued the interventions, and both treatments were well tolerated.

CONCLUSIONS

In youth with IGT or recently diagnosed type 2 diabetes, neither 3 months of glargine followed by 9 months of metformin nor 12 months of metformin alone halted the progressive deterioration of β-cell function. Alternate approaches to preserve β-cell function in youth are needed.

The SEARCH for Diabetes in Youth epidemiological study has highlighted a continued increase in the incidence of type 2 diabetes in adolescents age 10–19 years, particularly among ethnic minority groups. The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study demonstrated that in 50% of

RISE Coordinating Center, Rockville, MD
Corresponding author: Sharon L. Edelstein, rise@bsc.gwu.edu.
Received 10 April 2018 and accepted 13 May 2018.
Clinical trial reg. no. NCT01779375, clinicaltrials.gov.
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc18-0787/-/DC1.
*A complete list of the RISE Consortium Investigators can be found in the Supplementary Data online.
© 2018 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
See accompanying articles, pp. XXX and XXX.
youth with type 2 diabetes, initial assigned treatment failed, requiring the initiation of insulin therapy after an average follow-up of 3.9 years, which is in keeping with faster disease progression than reported in adults (1–3). In TODAY, lower β-cell function at baseline as well as a greater decline in β-cell function over time predicted worse glycemic control and treatment failure (4). Thus, interventions to preserve or improve β-cell function in youth are critically needed.

Metformin and insulin each has been shown to improve β-cell function in adults with impaired glucose tolerance (IGT) or recent-onset type 2 diabetes. The Diabetes Prevention Program demonstrated that metformin improves β-cell function and reduces diabetes progression by 31% over 3 years in adults with IGT (5,6). Weng et al. (7) showed in adults with newly diagnosed type 2 diabetes that <2 weeks of intensive insulin therapy improves and maintains β-cell function, resulting in prolonged remission from requiring diabetes medication. Whether such interventions have similar benefits in youth is unclear. The Restoring Insulin Secretion (RISE) Pediatric Medication Study was designed as a proof-of-principle trial to test in youth across a continuum of β-cell dysfunction from IGT to mild, recently diagnosed type 2 diabetes the hypothesis that initial short-term treatment with insulin glargine for 3 months followed by metformin for 9 months would preserve or improve β-cell function compared with metformin alone, with a sustained effect after withdrawal of therapy.

RESEARCH DESIGN AND METHODS

Study Protocol

The RISE Pediatric Medication Study was a four-center, randomized, open-label clinical trial funded by the National Institute of Diabetes and Digestive and Kidney Diseases. The rationale and methods have been described in detail elsewhere (8–10); additional specifics are provided in the Supplementary Data. Each center’s institutional review board approved the protocol. Written parental consent and child assent were obtained consistent with the Declaration of Helsinki and each center’s institutional review board guidelines. The protocol can be found at https://rise.bsc.gwu.edu/web/rise/collaborators.

Participants

A summary of study visits is shown in Supplementary Fig. 1, and a summary of participants enrolled and their rates of completion of study visits is shown in a CONSORT diagram (Supplementary Fig. 2). Enrollment occurred between July 2013 and April 2016. Youth age 10–19 years with a BMI ≥85th percentile for age and sex but ≤50 kg/m², IGT or recently diagnosed (≤6 months duration) type 2 diabetes, and Tanner stage ≥II (females, Tanner stage ≥II breast development; and males, testicular volume >3 mL) were eligible. Screening included a history and physical examination, laboratory tests, and a 75-g oral glucose tolerance test (OGTT). Eligibility criteria included the simultaneous presence of all the following: negative GAD and IA2 autoantibodies, fasting glucose ≥5 mmol/L, OGTT 2-h glucose ≥7.8 mmol/L, HbA₁c ≥8.0% (64 mmol/mol) if drug naïve. In youth with type 2 diabetes already taking metformin, eligibility was modified to HbA₁c ≤7.5% (58 mmol/mol) if on metformin for <3 months and ≥7.0% (53 mmol/mol) if on metformin for 3–6 months.

Final eligibility required ≥80% compliance with 3 weeks of placebo medication (or study-provided metformin if already taking metformin) and attendance at scheduled run-in visits. Eligible participants underwent a baseline hyperglycemic clamp and OGTT followed by random 1:1 treatment assignment by study site, stratified by glycemic status.

Interventions

The glargine followed by metformin group received 3 months of insulin glargine titrated at least twice weekly by a preset algorithm (Supplementary Study Methods) to achieve a fasting glucose of 4.4–5.0 mmol/L on the basis of daily self-monitored blood glucose (SMBG, Freestyle Lite, Abbott Laboratories, Lake Bluff, IL), which was followed immediately by 9 months of metformin (titrated to 1,000 mg twice daily). Youth already taking metformin and randomized to glargine therapy discontinued active metformin at the time of initiation of glargine treatment. The metformin group received metformin alone (titrated to 1,000 mg twice daily) for 12 months. Participants took their assigned intervention for 12 months, after which it was withdrawn, and follow-up continued while off study medication for an additional 3 months to determine the 15-month primary outcome of treatment durability. Anthropometrics, HbA₁c, and safety evaluations were performed every 3 months, and hyperglycemic clamps and OGTTs were repeated at 12 and 15 months (8–10) (Supplementary Fig. 1). Laboratory assessments were performed in a central laboratory at the University of Washington as summarized below and described in greater detail elsewhere (9).

Medication adverse effects, symptoms of hypoglycemia and hyperglycemia, and adherence (returned medication bottle pill count, returned insulin pen residual volume) were assessed at all study visits. A detailed algorithm was used for addressing hypoglycemia, hyperglycemia, and acute metabolic decompensation at each visit (Supplementary Study Methods). If protocol-specified HbA₁c safety thresholds were exceeded at any visit, outcome assessments were performed whenever possible. The participant was then withdrawn from the study and referred for additional diabetes treatment as appropriate. Safety was monitored by an independent data and safety monitoring board.

Procedures and Calculations

A two-step hyperglycemic clamp (11.1 mmol/L, >25 mmol/L) paired with the insulin secretagogue arginine at the second step was performed at baseline, 12 months, and 15 months as previously described (8–10). If the participant was on metformin, the last dose of metformin was taken the evening before the hyperglycemic clamp. The hyperglycemic clamp was used to quantify simultaneously insulin sensitivity (M/I) and three β-cell response measures: 1) steady-state (second-phase) C-peptide, 2) acute C-peptide response to arginine at maximal glycemic potentiation (ACPRmax), and 3) acute (first-phase) C-peptide response to glucose (ACPRg). M/I was calculated as the mean glucose infusion rate (M) at 100, 110, and 120 min of the clamp divided by the corresponding mean steady-state plasma insulin concentration (I) (11–13). Mean steady-state (second-phase) C-peptide and insulin concentrations were calculated at 100, 110, and 120 min (13). ACPRmax was calculated as the mean incremental response above concentrations before the arginine bolus (14) and ACPRg as the mean incremental
response above baseline for the first 10 min after glucose bolus (15).

The 15-month (3 months after discontinuation of metformin) steady-state C-peptide and ACPRmax, each paired with 15-month insulin sensitivity, represent the coprimary outcomes. These were paired to express the magnitude of the β-cell response as a function of the prevailing insulin sensitivity (15). Secondary outcomes from the hyperglycemic clamp included the 15-month ACPRg paired with the 15-month M/I and the 12-month C-peptide response measures (steady-state C-peptide, ACPRmax, ACPRg) each paired with M/I at the same time point.

A 3-h 75-g OGTT also was performed on a separate day and used to determine fasting and 2-h glucose at baseline, 12 months, and 15 months. If the participant was on metformin, the last dose of metformin was taken the evening before the OGTT. Additional HbA1c testing was done at baseline and 3, 6, 9, 12, and 15 months for robust phenotyping of participants over time.

Assays
Glucose was measured using the glucose hexokinase method on a Roche c501 autoanalyzer. C-peptide and insulin were measured by a two-site immunoenzymometric assay performed on the Tosoh 2000 autoanalyzer (Tosoh Bioscience, Inc., South San Francisco, CA). Interassay coefficients of variation on quality control samples with low, medium, medium-high, and high concentrations were ≤2.0% for glucose, ≤4.3% for C-peptide, and ≤3.5% for insulin.

Statistics
Data were accumulated centrally, and analyses were performed according to a prespecified analysis plan. For this proof-of-principle trial, we chose two measures of β-cell function as coprimary outcomes: clamp-derived steady-state C-peptide and ACPRmax at 15 months (both evaluated jointly with M/I). These two measures evaluate different components of β-cell function and were selected because there were no data in youth to determine whether one or the other was likely to change after the interventions.

No preliminary data were available in youth on the expected differences in either primary outcome after a period of intervention withdrawal (washout). Several unpublished analyses provided a range of possible differences between individuals taking medication and those taking placebo as well as expected correlations between baseline and follow-up measures. Therefore, sample size was based on a minimum effect size equal to the difference between the two groups divided by the SD in favor of the glargine followed by metformin group at a power of 80%. Because we targeted improvements in β-cell function, a one-sided significance level of 0.05 to detect a benefit of glargine followed by metformin was used for each comparison, with a conservative correlation of 0.5 between baseline and follow-up measures. Thirty-nine participants per arm (78 total) at the end of the washout provided ≥80% power to detect a minimum effect size of 0.57 in favor of glargine followed by metformin for either primary outcome measurement using baseline-adjusted ANCOVA. Ninety participants were sought, allowing for an ~10% loss to follow-up.

The primary analysis was the comparison of β-cell responses paired with M/I between treatment groups at 15 months, adjusted for baseline β-cell response and M/I. Joint models for β-cell response and M/I were fit simultaneously using seemingly unrelated regression techniques (16–18), which provide a two degrees of freedom χ² test of the treatment arm difference in the joint values of β-cell response and M/I between treatment groups. The same methods were used to compare treatment groups at 12 months.

To evaluate changes within each treatment arm over time, Hotelling T² distribution was used to test changes in β-cell responses and M/I simultaneously (19). Additional secondary analyses compared means across treatment arms at specific time points by using ANCOVA adjusted for the baseline value of the measure and by repeated-measures ANCOVA across the active 12-month intervention period adjusted for the baseline value of the measure.

Two participants had an HbA₁c elevation requiring study withdrawal before their 15-month primary outcome visit. The clamp-derived outcome data for these participants were imputed using the midpoint between zero and the lowest value in their respective treatment arm.

RESULTS
Demographic, Physical, and Metabolic Characteristics
We screened 236 youth and randomized 91 (Supplementary Fig. 2). Table 1 lists baseline demographic and metabolic characteristics of participants by treatment arm. The metformin alone group was slightly younger but not different in Tanner stage. All other baseline physical, metabolic, β-cell response, and insulin sensitivity measures were similar between treatment groups. Of the 91 participants, 21 with type 2 diabetes were receiving metformin at randomization or were previously exposed to it, with a similar distribution of metformin exposure and IGT versus type 2 diabetes status between treatment groups.

Adherence to Interventions
During weeks 11–12, the mean ± SD glargine dose in the glargine followed by metformin group was 0.7 ± 0.4 units/kg/day, and fasting blood glucose had decreased from a mean of 6.0 ± 0.8 mmol/L at the baseline OGTT to a fasting SMBG mean of 5.2 ± 0.7 mmol/L, with 50% achieving the 4.4–5.0 mmol/L goal (Fig. 1). As assessed by residual volume, 68% of participants were >80% compliant with the insulin. Metformin adherence by pill count was 88 ± 18% over the entire study, not differing by treatment group.

Treatment Effects on Temporal Changes in β-Cell Function
Figure 2 illustrates glucose and C-peptide concentrations during the hyperglycemic clamps performed at baseline, 12 months, and 15 months. Of note, identical target glucose concentrations of 11.1 and >25 mmol/L were achieved and not different between treatment groups at baseline, 12 months, and 15 months. Supplementary Table 1 shows β-cell responses and M/I by treatment group.

No significant differences were found between treatment groups at 12 or 15 months in either primary measure of β-cell function (e.g., response [steady-state C-peptide, ACPRmax] paired with M/I) or in the secondary measure of β-cell function (ACPPrg paired with M/I). Figure 3 shows a vector plot of changes from baseline to 12 and 15 months for each of the two coprimary clamp-derived β-cell responses (steady-state C-peptide, ACPRmax) paired with M/I, and Supplementary Fig. 3 shows the vector plot for the secondary β-cell response (ACPPrg paired with M/I). Explanations of the vector plots appear in the respective
Temporal Patterns of BMI and Glycemic Measures Over 15 Months

Several transient changes were seen in body size and glycemic parameters (Fig. 4). BMI did not differ between treatment groups at 12 or 15 months. However, BMI declined from baseline within the metformin alone group over the first 9 months, resulting in a significantly lower BMI across the 12-month intervention period in the metformin alone versus glargine followed by metformin group (P = 0.008) and specifically at 3 (P < 0.001), 6 (P < 0.02), and 9 (P < 0.04) months.

HbA1c did not significantly differ between treatment groups across the 12-month intervention period or at any individual time point (Fig. 4). However, compared with baseline, HbA1c declined significantly within the glargine followed by metformin group at 3 months while on glargine treatment (P < 0.03) and within both groups at 6 months (glargine followed by metformin P = 0.001, metformin alone P = 0.014) before rebounding to baseline levels in both groups at months 9 and 12, despite continued active metformin treatment. By 15 months, HbA1c had increased significantly from baseline in the glargine followed by metformin group (P < 0.03), ending at ~6% (42 mmol/mol) in both treatment groups.

No differences were found between treatment groups in fasting or OGTT 2-h glucose concentrations at 12 or 15 months. Within the glargine followed by metformin group, fasting glucose was not different at 12 months compared with baseline but rose higher than baseline by 15 months (off treatment) (P = 0.02). Within the glargine followed by metformin group, 2-h glucose was significantly lower than baseline at 12 months (P = 0.02) but

**Table 1—Baseline demographic and physical characteristics, insulin sensitivity, and β-cell responses from the hyperglycemic clamp and OGTT by treatment group**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Glargine followed by metformin (n = 44)</th>
<th>Metformin alone (n = 47)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>27 (61.4)</td>
<td>38 (80.9)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>14.9 ± 2.0</td>
<td>13.9 ± 2.1*</td>
</tr>
<tr>
<td>Tanner stage V</td>
<td>32 (72.7)</td>
<td>25 (53.2)</td>
</tr>
<tr>
<td>Race/ethnicity, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>13 (29.5)</td>
<td>12 (25.5)</td>
</tr>
<tr>
<td>Black</td>
<td>14 (31.8)</td>
<td>9 (19.1)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>14 (31.8)</td>
<td>20 (42.6)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (6.8)</td>
<td>6 (12.8)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>102.0 ± 25.7</td>
<td>97.7 ± 23.3</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>36.5 ± 6.4</td>
<td>36.9 ± 6.4</td>
</tr>
<tr>
<td>BMI percentile</td>
<td>98.4 ± 2.5</td>
<td>98.8 ± 1.3</td>
</tr>
<tr>
<td>BMI z score</td>
<td>2.3 ± 0.4</td>
<td>2.4 ± 0.3</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>109.8 ± 15.8</td>
<td>109.6 ± 12.4</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mol/mmol</td>
<td>5.7 ± 0.6</td>
<td>5.7 ± 0.6</td>
</tr>
<tr>
<td>IGT, n (%)</td>
<td>26 (59)</td>
<td>28 (60)</td>
</tr>
<tr>
<td>Type 2 diabetes, n (%)</td>
<td>18 (41)</td>
<td>19 (40)</td>
</tr>
<tr>
<td>Metformin use at baseline, n (%)</td>
<td>10 (22.7)</td>
<td>11 (23.4)</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>120.7 ± 7.8</td>
<td>119.5 ± 8.7</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>67.6 ± 7.7</td>
<td>70.1 ± 7.9</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>9 (20.5)</td>
<td>15 (31.9)</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>1.11 (0.39, 3.14)</td>
<td>1.17 (0.45, 3.06)</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.0 ± 0.3</td>
<td>1.0 ± 0.2</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>2.3 ± 0.8</td>
<td>2.1 ± 0.6</td>
</tr>
<tr>
<td>Hyperglycemic clamp variables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting glucose (mmol/L)</td>
<td>6.04 ± 0.85</td>
<td>6.11 ± 1.10</td>
</tr>
<tr>
<td>Fasting C-peptide (mmol/L)</td>
<td>1.63 ± 0.57</td>
<td>1.82 ± 0.58</td>
</tr>
<tr>
<td>Fasting insulin (pmol/L)</td>
<td>211.1 (54.8, 813.5)</td>
<td>247.4 (74.1, 825.4)</td>
</tr>
<tr>
<td>Steady-state C-peptide (mmol/L)</td>
<td>5.22 (2.44, 11.15)</td>
<td>5.09 (2.32, 11.19)</td>
</tr>
<tr>
<td>ACPRmax (nmol/L)</td>
<td>7.29 (3.29, 16.16)</td>
<td>8.12 (3.42, 19.26)</td>
</tr>
<tr>
<td>ACPRg (nmol/L)</td>
<td>1.06 (0.10, 11.66)</td>
<td>1.14 (0.14, 9.02)</td>
</tr>
<tr>
<td>Glucose infusion rate (M) (mmol/kg/min)</td>
<td>0.025 ± 0.013</td>
<td>0.023 ± 0.010</td>
</tr>
<tr>
<td>Steady-state insulin (I) (pmol/L)</td>
<td>1.391 (281, 6874)</td>
<td>1.371 (286, 6572)</td>
</tr>
<tr>
<td>M/I (× 10^-5 mmol/kg/min per pmol/L)</td>
<td>1.60 (0.35, 7.38)</td>
<td>1.54 (0.35, 6.76)</td>
</tr>
<tr>
<td>OGTT variables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting glucose (mmol/L)</td>
<td>6.0 ± 0.8</td>
<td>6.1 ± 1.1</td>
</tr>
<tr>
<td>2-h glucose (mmol/L)</td>
<td>10.2 ± 2.5</td>
<td>10.2 ± 2.8</td>
</tr>
</tbody>
</table>

Data are mean ± SD or geometric mean (95% CI) for nonnormally distributed variables. *P < 0.03; all other P values were not significant.
no longer different from baseline at 15 months. Within the metformin alone group, no significant changes were found in fasting or 2-h glucose at 12 months while on active treatment or at 15 months.

Safety Outcomes

Seven serious adverse events occurred (one hospitalization each for suicidal ideation/anxiety, newly diagnosed Ewing sarcoma, otitis externa, appendicitis/appendectomy, and pneumonia and two hospitalizations for tonsillectomy/adenoidectomy), all deemed unrelated to the study interventions. Other non-serious adverse events are summarized in Supplementary Table 2. No participants had severe hypoglycemia or acute metabolic decompensation as defined in Supplementary Study Methods. Accordingly, no participants required rescue therapy with insulin.

Over the 15 months, three participants in the glargine followed by metformin group with IGT at baseline and none in the metformin alone group with IGT at baseline developed diabetes as defined by OGTT criteria and HbA1c ≥6.5% (48 mmol/mol) (20). In each treatment group, three participants met hyperglycemic criteria for study withdrawal. The last outcome visits for these participants were three at 15 months in the glargine followed by metformin group and two at 12 and one at 15 months in the metformin alone group, after which the participants were withdrawn from the study and returned to their primary diabetes provider for additional diabetes treatment.

CONCLUSIONS

In youth along the glycemic continuum of IGT to mild, recently diagnosed type 2 diabetes, we tested whether initial short-term treatment with insulin glargine for 3 months followed by metformin for 9 months would preserve or improve β-cell function compared with metformin alone for 12 months and a sustained effect after withdrawal of therapy. No significant differences were found between groups in β-cell function at 12 or 15 months, and all β-cell measures at 12 months (on treatment) and 15 months (off treatment) were worse than at baseline. Thus, the only two agents approved for treating type 2 diabetes in youth both failed to preserve or improve β-cell function during or after withdrawal of treatment in youth with IGT or recently diagnosed type 2 diabetes.

Trials of insulin therapy in adults with IGT or early type 2 diabetes support the concept that early use of insulin may have a beneficial long-term effect on dysglycemia. In the Outcome Reduction With Initial Glargine Intervention (ORIGIN Trial), adults with high cardiovascular disease risk and prediabetes were treated with insulin glargine to a similar target glucose (≤5.3 mmol/L) as we achieved (21). A median of 3.3 months after insulin discontinuation, a similar duration of durability as we evaluated, those with prediabetes randomized to glargine treatment had a 20% reduction in the odds of developing diabetes on the basis of OGTT criteria compared with standard care (21). In adults with recently diagnosed type 2 diabetes, Weng et al. (7) found that up to 2 weeks of intensive insulin therapy as either multiple daily injections or continuous subcutaneous infusion, an even shorter treatment duration than we tested, resulted in remission and no need for diabetes medications 1 year later in 45% and 51% of participants, respectively. Furthermore, after the 2-week insulin treatment, the β-cell response increased, and this improvement was sustained in the participants who remained in remission while off medications. Although the study by Weng et al. suggested benefit from <2 weeks of insulin treatment, we saw no effect from a 3-month duration of treatment, which is longer than that used by Weng et al. yet brief enough to realistically consider in youth. Moreover, we chose a target glucose lower than that used in the

Figure 1—Insulin doses and corresponding fasting glucose values over time while on glargine treatment. A: Mean fasting morning SMBG values every 2 weeks over 12 weeks. B: Mean glargine dose corresponding to each SMBG value. C: Corresponding percentage of participants who achieved the goal fasting SMBG of 4.4–5.0 mmol/L every 2 weeks. Data are mean (95% CI).
ORIGIN Trial to maximize the effect of the insulin treatment. To further increase the likelihood of insulin having an effect, we added the oral glucose-lowering agent metformin shown in the Diabetes Prevention Program to be effective in preventing the development of diabetes in adults with IGT (6). In contrast to the adult studies, we found no durable effect of insulin glargine targeted to achieve a plasma glucose of 4.4–5.0 mmol/L followed by metformin on measures of β-cell function or glycemia in youth. Furthermore, the lack of a beneficial effect of metformin alone on β-cell function, even when youth were still on the medication at 12 months, contrasts with observations after 1 year of therapy in adults with IGT (5) or type 2 diabetes (22). Although a longer duration of insulin treatment may have had more of an effect on β-cell function, longer-term treatment also may have led to additional weight gain, with an uncertain net balance of benefit and harm. Moreover, the injections and glucose monitoring required for longer-term insulin treatment might be met with resistance by youth, particularly those who are not yet diagnosed with diabetes.

The RISE Consortium (9) reported that youth with IGT or recently diagnosed, drug-naïve type 2 diabetes are profoundly more insulin resistant, have greater insulin responses for any degree of insulin sensitivity, and have lower hepatic insulin clearance than adults. This finding, combined with the poor response of youth to the RISE interventions, suggests that although β-cell dysfunction is the foundation for dysglycemia in both age-groups, greater β-cell demand may place youth at a higher risk for more-rapid β-cell damage. Additional support for this interpretation comes from the apparently more-rapid progression of type 2 diabetes observed in youth in the TODAY study than in a similar study in adults treated with the same glucose-lowering medications (2,3). Furthermore, the current observation of a lack of a beneficial effect of metformin on β-cell function in youth after 12 months of therapy contrasts with the improvement in β-cell function observed in adults with IGT (5) or type 2 diabetes (22). The RISE Adult Medication Study, which includes these same two intervention arms as part of a four-arm study, should provide additional insight into these differences (8).

The current study has several strengths, including the randomized design and a robust, multicenter approach to quantification of insulin sensitivity and β-cell responses to both glucose and

**Figure 2**—Glucose and C-peptide values during the hyperglycemic clamp at baseline, after 12 months of treatment, and 3 months after discontinuing the intervention (15 months). The glargine followed by metformin group (n = 44 [green]) and the metformin alone group (n = 47 [brown]) are shown. The steady-state glucose targets were 11.1 mmol/L between 90 and 120 min and >25 mmol/L at 150 min. Data are mean ± SEM.
nonglucose secretagogue arginine performed to provide thorough, longitudinal phenotyping of participants. By quantifying both insulin sensitivity and β-cell responses simultaneously, we were able to account for the well-recognized relationship between insulin sensitivity and β-cell responsivity (15) and thus gain mechanistic insight into the effect of the interventions on β-cell function over time. Of key importance for this multicenter study, we reached matching levels of hyperglycemia during each of three repeated hyperglycemic clamp tests, showing a high degree of both reproducibility and reliability for the outcome measures across time points and across study sites. Study retention and metformin adherence also were excellent across study sites. Study retention and metformin adherence also were excellent across study sites. Study retention and metformin adherence also were excellent across study sites.

The RISE Consortium acknowledges the support and input of the RISE Trial data and safety monitoring board and Barbara...
Linder, the National Institute of Diabetes and Digestive and Kidney Diseases program official for RISE. The Consortium is also grateful to the participants, who by volunteering, are furthering our ability to reduce the burden of diabetes.

**Funding.** RISE is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-094406, U01-DK-094410, U01-DK-094431, U01-DK-094448, U01-DK-094467, P30-DK-017047, P30-DK-020595, P30-DK-04573S, P30-DK-097512), the National Center for Advancing Translational Sciences (UL1-TR-000430, UL1-TR-001082, UL1-TR-001108, UL1-TR-001855, UL1-TR-001857, UL1-TR-001858, UL1-TR-001863), the Department of Veterans Affairs, and Kaiser Permanente Southern California. Additional financial and material support from the American Diabetes Association, Allergan, Apollo Endosurgery, Abbott Laboratories, and Novo Nordisk is gratefully acknowledged.

**Duality of Interest.** S.A.A. and S.E.K. serve as paid consultants on advisory boards for Novo Nordisk. K.J.M. holds an investigator-initiated research support from Allergan and Apollo Endosurgery. No other potential conflicts of interest relevant to this article were reported.

**Author Contributions.** Writing Group: Kristen J. Nadreau (chair), Tamara S. Hannon, Sharon L. Edelstein, Silva A. Arslanian, Sonia Caprio, Ellen W. Leschek, Philip S. Zeitler, Thomas A. Buchanan, David M. Ehrmann, Kieren J. Mather and Steven E. Kahn. K.J.N. wrote the first draft. K.J.N., S.L.E., S.A.A., S.C., E.W.L., T.A.B., D.A.E., K.J.M., and S.E.K. (chair) comprise the steering committee (principal investigator at each site, the data coordinating center, and the National Institute of Diabetes and Digestive and Kidney Diseases project scientist) and designed and implemented the study, contributed to the discussion, and edited the manuscript. K.J.N., T.S.H., S.L.E., S.A.A., S.C., P.S.Z., E.W.L., T.A.B., D.A.E., K.J.M., and S.E.K. researched data. S.L.E. performed all data analyses. K.J.N., S.L.E., and S.E.K. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Prior Presentation.** Parts of this study were presented in oral form at the 78th Scientific Sessions of the American Diabetes Association, Orlando, FL, 22–26 June 2018.

**References**

---

**Figure 4**—BMI and glycemia over time. BMI (A), HbA1c (B), fasting glucose (C), and OGTT 2-h glucose over 15 months (D). In the glargine followed by metformin group (n = 44 [green]), glargine insulin was given from baseline to 3 months followed by metformin from months 3 through 12. In the metformin alone group (n = 47 [brown]), metformin was given from baseline through 12 months. Treatment was discontinued in both groups at 12 months. Data are mean ± SEM. *P < 0.05 for the difference between treatment groups at the specified time point; §P < 0.05 for the difference within treatment group between the specified time point and baseline.